mebeverine

10/01/1995 - "A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome."
02/17/2022 - "The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review."
11/02/1978 - "A double-blind clinical longterm trial with the musculotropic agent Mebeverine in 30 patients, suffering from the irritable colon syndrome, is reported. "
10/01/2019 - "Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome?"
12/01/2014 - "The use of mebeverine in irritable bowel syndrome. "

01/01/2013 - "Duspatalin is effective in relieving biliary disfunction symptoms, Oddy's sphincter hypertonicity in particular, but has little effect on intestinal dyskinesia. "
01/01/2010 - "The therapeutic efficacy of duspatalin was evaluated in 72 patients with chronic cholecystitis and dyskinesia of the biliary tract (BT). "
01/01/2009 - "The therapeutic efficacy of duspatalin was evaluated in 69 patients with chronic cholecystitis and dyskinesia of the biliary tract (BT). "

01/01/2007 - "[Assessment of the efficacy of mebeverine in the complex therapy of chronic noncalculolis cholecystitis and biliary dysfunction]."
01/01/2010 - "The therapeutic efficacy of duspatalin was evaluated in 72 patients with chronic cholecystitis and dyskinesia of the biliary tract (BT). "
01/01/2009 - "The therapeutic efficacy of duspatalin was evaluated in 69 patients with chronic cholecystitis and dyskinesia of the biliary tract (BT). "
01/01/2010 - "Supplementation of duspatalin to the combined therapy in the patients with chronic cholecystitis shown to exert a pronounced therapeutic effect. "
01/01/2009 - "Supplementation of duspatalin to the combined therapy in the patients with chronic cholecystitis shown to exert a pronounced therapeutic effect. "

02/07/2010 - "The efficacy of mebeverine 200 mg compared to mebeverine 135 mg indicated RRs of 1.12 (95% CI: 0.96-1.3, P = 0.168) for clinical or global improvement and 1.08 (95% CI: 0.87-1.34, P = 0.463) for relief of abdominal pain. "
02/17/2022 - "Only three studies showed no improvement after mebeverine treatment in terms of the severity of abdominal pain or discomfort. "
02/17/2022 - "Six studies reported a significant decrease in abdominal pain after mebeverine treatment (p-values ranging from <0.05 to <0.001). "
01/01/2014 - "Mebeverine for pediatric functional abdominal pain: a randomized, placebo-controlled trial."
06/01/2021 - "The second case is of a 53-year-old man who was also initially diagnosed with IBS and was treated with mebeverine 200mg twice daily for eight weeks before presenting to the emergency department with worsening abdominal pain. "

07/01/2003 - "A double-blind randomised, placebo-controlled trial evaluating the influence of oral long-acting muscle relaxant (Mebeverine MR), and insufflation with CO(2) on pain associated with barium enema."
05/01/2022 - "After the fourth week of intervention, symptoms of pain, bloating, and reflux showed a significant decrease in the ZT group compared to the placebo and mebeverine groups (P <0.05). "
05/01/2006 - "IBS patients treated with mebeverine experienced low quality of life and suffered from severe pain. "
07/01/2003 - "Having Mebeverine as a pre-medication did not significantly lower pain scores compared with placebo, and decreased the amount of benefit received from the CO(2). "
05/03/1982 - "There was a significant reduction in spasm on fluoroscopy and reported pain and discomfort in the mebeverine group. "